- WuXi AppTec reported Q1 2026 revenue of RMB 12.44 billion, up 28.8% year-over-year, with adjusted non-IFRS net profit rising 71.7% to RMB 4.60 billion.
- The company’s backlog reached RMB 59.77 billion, supported by continued expansion of its CRDMO pipeline and operational growth.
WuXi AppTec reported financial results for the first quarter ending March 31, 2026, with total revenue reaching RMB 12.44 billion, representing a 28.8% year-over-year increase. Adjusted non-IFRS net profit rose 71.7% to RMB 4.60 billion, while adjusted gross profit margin improved to 50.4%.
The company attributed the performance to continued growth across its integrated CRDMO platform. Its backlog for continuing operations reached RMB 59.77 billion as of March 31, 2026, reflecting sustained demand and increased business visibility. Adjusted operating cash flow also increased 21.7% year-over-year to RMB 3.69 billion.
“In the first quarter, our business segments delivered broad-based momentum, with strong growth in both revenue and profit. Our backlog of RMB 59.8 billion for Continuing Operations reflects the strength of our unique CRDMO business model, efficiently enabling the growing needs of our customers.”
Dr. Ge Li, Chairman and CEO of WuXi AppTec
WuXi Chemistry remained the largest contributor, generating RMB 10.62 billion in revenue, up 43.7% year-over-year, supported by pipeline progression and capacity ramp-up. The small molecule development and manufacturing pipeline expanded to 3,550 molecules, including 89 commercial projects and 94 in phase III. The company added 328 new molecules during the quarter, indicating continued growth in its contract manufacturing business.
Other segments also reported growth. WuXi Testing revenue increased 27.4% year-over-year to RMB 1.13 billion, while WuXi Biology revenue rose 10.1% to RMB 0.67 billion. The company stated that new modality services, including nucleic acids, conjugates, multispecific antibodies, and peptides, contributed more than 30% of revenue in certain segments, supporting its broader CRDMO strategy.
